Eterna Therapeutics Inc
Change company Symbol lookup
Select an option...
ERNA Eterna Therapeutics Inc
TANH Tantech Holdings Ltd
OMGA Omega Therapeutics Inc
INBS Intelligent Bio Solutions Inc
PAYX Paychex Inc
PYR Pyrogenesis Canada Inc
PM Philip Morris International Inc
GWAV Greenwave Technology Solutions Inc
SLNO Soleno Therapeutics Inc
VRPX Virpax Pharmaceuticals Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value

Eterna Therapeutics Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies using messenger ribonucleic acid (RNA) (mRNA) cell engineering technology. The Company has a portfolio of over 100 patents covering mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system, which the Company collectively refers to as its mRNA technology platform. Its mRNA gene-editing technology is designed to delete, insert, and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to fight cancer.

Closing Price: $2.13

Day's Change: 0.04 (1.91%)

Bid: --

Ask: --

B/A Size: --

Day's High: 2.23

Day's Low: 2.05

Volume (Light) Volume: 4,173 10-day average volume: 10,197: 4,173

Unable to locate that news article. Back to news results

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and